Dr. Jen Rogers on the Use of CB-CAPs to Assess Disease Activity in SLE

Tyler O’Malley on Validation of CB-CAPs Distinguishing SLE from Fibromyalgia

How can a multianalyte assay panel help distinguish SLE from fibromyalgia and chronic localized pain? And what impact does this have on rheumatologists working to help determine their patients’ conditions? Join Exagen and Tyler O’Malley, Senior Director of Clinical Affairs for Exagen, as he breaks down the abstract, Multi-Center Validation of Cell-Bound Complement Activation Products a Multianalyte Assay Panel Distinguishing Systemic Lupus Erythematosus from Primary Fibromyalgia. Tyler dives into how the study came to be and its clinical importance to both providers and patients.

Dr. Jen Rogers on the Use of CB-CAPs to Assess Disease Activity in SLE

What is the Type 1 vs Type 2 Lupus Model? How does it shape the care and management of lupus patients? And what impact does it have on the future of drug development to address Type 2 symptoms? Join Exagen and Dr. Jen Rogers, Director of the Duke Lupus Clinic as she breaks down the abstract, The Use of Cell-bound Complement Activation Product to Assess Disease Activity in SLE, how the study came to be, and its clinical importance to both providers and patients.

Dr. Anca Askanase on PC4d Predicting Thrombotic Events in SLE

How does PC4d aid in the prediction of future thrombotic events in those with SLE? And how can it be utilized by clinicians to help their lupus patients? Join Exagen and Dr. Anca Askanase, founder and clinical director of Columbia’s new Lupus Center and the director of Rheumatology Clinical Trials, as she breaks down the abstract, Role of PC4d in Predicting Risk of Thrombotic Events in SLE, how the study came to be, and its clinical importance to both providers and patients.